Evaluation of the safety, immunogenicity and efficacy of a new live-attenuated lumpy skin disease vaccine in India.

ABSTRACT: Lumpy skin disease (LSD) was reported for the first time in India in 2019 and since then, it has become endemic. Since a homologous (LSD-virus based) vaccine was not available in the country, goatpox virus (GPV)-based heterologous vaccine was authorized for mass immunization to induce protection against LSD in cattle. This study describes the evaluation of safety, immunogenicity and efficacy of a new live-attenuated LSD vaccine developed by using an Indian field strain, isolated in 2019 from cattle. The virus was attenuated by continuous passage (P = 50) in Vero cells. The vaccine (50^th LSDV passage in Vero cells, named as Lumpi-ProVac^Ind) did not induce any local or systemic reaction upon its experimental inoculation in calves (n = 10). At day 30

SUBMITTER: Kumar N 

PROVIDER: S-EPMC10038050 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature